Photo from Yelak Biru/X
May 17, 2024, 13:11
Yelak Biru: Kite and Arcellx have announced plans to commence a Phase III clinical trial for myeloma
Yelak Biru, President and CEO of the International Myeloma Foundation, shared on X: .
“We need more options in the multiple myeloma toolbox: Kite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of anitocabtagene autoleucel (anito-cel), for myeloma.
Anito-cel is a (BCMA CAR) T-cell therapy. Via Clinical Trials Arena.”
Source: Yelak Biru/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39